Managed by Regeneron Pharmaceuticals, Inc. • Latest filing Q4 2025
Overlap peers will appear here as data populates
Related fund suggestions coming soon.
| — |
| 5 | N NTLA — | $64M | 3.70M | 0.00% | — |
| 6 | N NTLA — | $43.2M | 3.70M | 0.00% | — |
| 7 | N NTLA — | $34.7M | 3.70M | 0.00% | — |
| 8 | N NTLA — | $33.3M | 3.70M | 0.00% | — |
| 9 | N NTLA — | $26.3M | 3.70M | 0.00% | — |
| 10 | B BG — | $6.2M | 1.25M | 0.00% | — |
| 11 | B BG — | $3.7M | 1.25M | 0.00% | — |
| 12 | A ACET — | $931K | 968.2K | 0.00% | — |
| 13 | ? N/A — | $845K | 180.9K | 0.00% | — |
| 14 | ? N/A — | $820K | 180.9K | 0.00% | — |
| 15 | ? N/A — | $791K | 180.9K | 0.00% | — |
| 16 | A ACET — | $784K | 968.2K | 0.00% | — |
| 17 | A ACET — | $731K | 968.2K | 0.00% | — |
| 18 | A ACET — | $591K | 968.2K | 0.00% | — |
| 19 | A ACET — | $510K | 60.5K | 0.00% | — |
| 20 | ? N/A — | $389K | 180.9K | 0.00% | — |